Darleukin is under clinical development by Philogen and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Darleukin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Darleukin overview
Darleukin (L19-IL2) is under development for the treatment of non-small cell lung cancer and melanoma. The drug candidate is administered by intravenous route. The drug candidate is a fusion protein of the human antibody L19 and the human cytokine IL-2. It is developed based on immunocytokine technology. It was also under development for the treatment of renal cell carcinoma as the first and third line of therapy, lymphoma and advanced pancreatic cancer in combination with gemcitabine and oligometastatic solid tumors including head and neck cancer squamous cell carcinoma, colorectal cancer, renal cell carcinoma, relapsed or refractory diffuse large B-cell lymphoma.
Philogen overview
Philogen is a biotechnology company that develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company’s product portfolio include Dodekin, Dekavil, NidlegyTM, Fibromun, Darleukin, and ABBV-022. The company provides dekavil and tetravil and others targeted at the treatment of severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. It offers DNA-encoded chemical libraries, antibody drug conjugates, immunocytokines, and antibody libraries, discovery of vascular targets, vascular targeting and easy iodine technology. The company is also advancing clinical development programs for the treatment of cancer and of chronic diseases. Philogen is headquartered in Siena, Italy.
For a complete picture of Darleukin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
